S. R. Schill & Associates Sells 1,192 Shares of Johnson & Johnson (NYSE:JNJ)

S. R. Schill & Associates lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 18.2% during the third quarter, Holdings Channel reports. The firm owned 5,362 shares of the company’s stock after selling 1,192 shares during the period. Johnson & Johnson makes up approximately 0.5% of S. R. Schill & Associates’ portfolio, making the stock its 24th largest position. S. R. Schill & Associates’ holdings in Johnson & Johnson were worth $876,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. Price T Rowe Associates Inc. MD lifted its holdings in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after acquiring an additional 3,912,430 shares during the period. Legal & General Group Plc lifted its holdings in Johnson & Johnson by 2.3% during the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock worth $3,344,295,000 after acquiring an additional 421,779 shares during the period. FMR LLC lifted its holdings in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Johnson & Johnson by 0.3% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after acquiring an additional 24,505 shares during the period. Institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the sale, the executive vice president now owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the completion of the sale, the vice president now directly owns 114,676 shares of the company’s stock, valued at approximately $18,864,202. The disclosure for this sale can be found here. Insiders sold a total of 300,750 shares of company stock valued at $52,311,677 over the last 90 days. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $174.88 on Thursday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business has a 50-day simple moving average of $176.22 and a 200 day simple moving average of $171.59. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The stock has a market cap of $457.22 billion, a price-to-earnings ratio of 24.36, a PEG ratio of 3.45 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The business had revenue of $23.79 billion during the quarter, compared to analysts’ expectations of $23.44 billion. During the same period in the previous year, the business earned $2.60 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson declared that its board has authorized a share repurchase program on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 1.2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.58%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of recent research reports. Citigroup raised their target price on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. Atlantic Securities decreased their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Raymond James decreased their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Barclays initiated coverage on Johnson & Johnson in a research report on Monday, October 17th. They issued an “equal weight” rating and a $175.00 target price for the company. Finally, Credit Suisse Group started coverage on Johnson & Johnson in a research report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 target price for the company. Seven research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $182.42.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.